Inventor
PEI TAO
US46 patents
⚠️ This page may combine multiple inventors who share the name “PEI TAO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ARROWHEAD PHARMACEUTICALS INC
33 patentsUS10450565B2Oct 22, 2019
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
ARROWHEAD PHARMACEUTICALS INC15 citations94
US11203756B2Dec 21, 2021
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
ARROWHEAD PHARMACEUTICALS INC5 citations84
US10294474B2May 21, 2019
Targeting ligands
ARROWHEAD PHARMACEUTICALS INC15 citations84
US10597657B2Mar 24, 2020
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
ARROWHEAD PHARMACEUTICALS INC6 citations83
US10246709B2Apr 2, 2019
Targeting ligands for therapeutic compounds
ARROWHEAD PHARMACEUTICALS INC10 citations83
US10780108B2Sep 22, 2020
RNAi agents for Hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC5 citations82
US10662427B2May 26, 2020
Compositions and methods for inhibiting gene expression of LPA
ARROWHEAD PHARMACEUTICALS INC6 citations82
US9932586B2Apr 3, 2018
Compositions and methods for inhibiting gene expression of LPA
ARROWHEAD PHARMACEUTICALS INC9 citations82
US11884920B2Jan 30, 2024
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
ARROWHEAD PHARMACEUTICALS INC2 citations73
US11590156B2Feb 28, 2023
RNAi agents for hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC2 citations72
US11517584B2Dec 6, 2022
RNAi agents for Hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC2 citations72
US11214801B2Jan 4, 2022
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
ARROWHEAD PHARMACEUTICALS INC3 citations72
US11180529B2Nov 23, 2021
Alpha-v beta-6 integrin ligands and uses thereof
ARROWHEAD PHARMACEUTICALS INC3 citations71
US11174481B2Nov 16, 2021
Targeting ligands
ARROWHEAD PHARMACEUTICALS INC3 citations71
US11629349B2Apr 18, 2023
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC3 citations70
US11549112B1Jan 10, 2023
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC3 citations70
US12441756B2Oct 14, 2025
5′-cyclo-phosphonate modified nucleotides
ARROWHEAD PHARMACEUTICALS INC0 citations62
US12365899B2Jul 22, 2025
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
ARROWHEAD PHARMACEUTICALS INC0 citations62
US12116573B2Oct 15, 2024
Targeting ligands for therapeutic compounds
ARROWHEAD PHARMACEUTICALS INC0 citations62
US11078227B2Aug 3, 2021
5′-cyclo-phosphonate modified nucleotides
ARROWHEAD PHARMACEUTICALS INC0 citations62
US11214802B2Jan 4, 2022
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations61
US10590416B2Mar 17, 2020
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
ARROWHEAD PHARMACEUTICALS INC1 citations61
US12173086B2Dec 24, 2024
Alpha-v beta-6 integrin ligands and uses thereof
ARROWHEAD PHARMACEUTICALS INC0 citations60
US11492624B2Nov 8, 2022
RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
ARROWHEAD PHARMACEUTICALS INC1 citations60
US11912997B2Feb 27, 2024
RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations59
US12054718B2Aug 6, 2024
RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations58
US12551569B2Feb 17, 2026
RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations56
US12378558B2Aug 5, 2025
RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations56
US11845937B2Dec 19, 2023
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC1 citations55
US12110492B2Oct 8, 2024
RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations47
US12503696B2Dec 23, 2025
RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations46
US12582668B2Mar 24, 2026
Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)
ARROWHEAD PHARMACEUTICALS INC0 citations45
US12442002B2Oct 14, 2025
RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations44
INT FLAVORS & FRAGRANCES INC
6 patentsUS7794768B2Sep 14, 2010
Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions
INT FLAVORS & FRAGRANCES INC6 citations72
US7427421B2Sep 23, 2008
Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions
INT FLAVORS & FRAGRANCES INC2 citations61
US7541055B2Jun 2, 2009
Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions
INT FLAVORS & FRAGRANCES INC2 citations58
US7329767B2Feb 12, 2008
Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof
INT FLAVORS & FRAGRANCES INC3 citations58
US8007849B2Aug 30, 2011
Unsaturated cyclic and acyclic carbamates exhibiting taste and flavor enhancement effect in flavor compositions
INT FLAVORS & FRAGRANCES INC1 citations51
US7615661B2Nov 10, 2009
Thioester compounds and their use in fragrance or flavor applications
INT FLAVORS & FRAGRANCES INC1 citations48